Compass Pathways surged Monday on growing enthusiasm for the company's psilocybin-based approach to treatment-resistant ...

A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...

Recent attention on COMPASS Pathways (CMPS) centers on its first quarter 2026 earnings and a series of key regulatory steps for COMP360 in treatment resistant depression, including a rolling FDA New ...

Michael Davis was appointed as the acting head of the FDA’s Center for Drug Evaluation and Research. ・Davis previously served as chief medical officer at Usona Institute, where he helped advance ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Today, the biotechnology sector is witnessing a significant rally, with Compass Pathways (NASDAQ:CMPS) leading the charge. As the company nears the finish line for its Phase 3 clinical trials, a ...

Fintel reports that on November 5, 2025, Morgan Stanley maintained coverage of COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) with a Overweight recommendation. As of October 30, 2025, the ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...

Compass Pathways may be the first to benefit from an accelerated approval process.